Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.32%72.110.9%$619.68m
CELGCelgene Corporation
0.06%127.651.1%$445.33m
AMGNAmgen Inc.
-0.31%167.291.1%$418.48m
BIIBBiogen Inc.
-0.93%281.771.2%$356.38m
REGNRegeneron Pharmaceuticals, Inc.
0.85%467.982.7%$321.83m
VRTXVertex Pharmaceuticals Incorporated
-0.28%148.131.9%$264.60m
ALXNAlexion Pharmaceuticals, Inc.
-0.91%133.401.9%$217.97m
ILMNIllumina, Inc.
-0.98%189.323.5%$216.35m
SRPTSarepta Therapeutics, Inc.
-0.46%36.7019.8%$138.44m
INCYIncyte Corporation
-0.45%121.192.6%$130.95m
CLVSClovis Oncology, Inc.
2.99%71.9618.0%$129.20m
KITEKite Pharma, Inc.
3.29%130.1816.1%$121.84m
TSROTESARO, Inc.
4.41%113.8614.7%$121.68m
AAgilent Technologies, Inc.
0.62%61.241.5%$119.01m
BMRNBioMarin Pharmaceutical Inc.
-0.07%80.924.4%$108.58m

Company Profile

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.